Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Review Article

Pharmaco-Audiology Vigilance in the Treatment of Adult Patients with HIV/Aids: Ototoxicity Monitoring Protocol Recommendation

Author(s): Katijah Khoza-Shangase*

Volume 20, Issue 1, 2020

Page: [33 - 42] Pages: 10

DOI: 10.2174/1871526518666181016102102

Price: $65

Abstract

South Africa is considered the epicenter of HIV/AIDS with a high rate of TB infection as well. Links have been established between treatments of these conditions to ototoxicity. However, no standardized and systematic ototoxicity monitoring exists within the clinical sites where these conditions are treated, with very minimal and adhoc involvement of audiologists as part of the treatment team. With 3.4 million HIV-infected South Africans being reported to have been on antiretroviral drugs by the end of March 2016; with universal coverage being the target, it is important that ototoxicity monitoring becomes part of the treatment plan. The objective of the current paper is to propose an ototoxicity monitoring protocol that can be implemented within this population to ensure that systematic data are collated in order for evidence-based protocols to be adopted within the South African context. Such a protocol will also allow for early identification and intervention of ototoxic hearing loss within this population. Enough evidence exists to support implementation of standardized protocols that will allow for proper, accurate, efficient, and reliable comparisons of data within and between patients; as well as between and within treatment sites – both locally and internationally. It is hoped that implementation of such a monitoring protocol will also have significant implications for the expanded role of the audiologist in the drug development process, affording evidence-based benefit-risk assessments of drugs in the market for this population.

Keywords: Audiology, HIV, otoacoustic emissions, ototoxicity monitoring, pharmaco-audiology, vigilance.

[1]
UNAIDS. HIV/AIDS, 2019. Available from : http://www.unaids.org/en/resources/fact-sheet
[2]
Shisana, O.; Rehle, T.; Simbayi, L. South African national HIV prevalence, incidence and behaviour survey 2014. 24 July 2016. Available from : http://www.hsrc.ac.za/uploads/page Content/4565/SABSSM (Retrieved from Human Science Research Council)
[3]
Davies, N.E.C.G. Fixed-dose combination for adults accessing antiretroviral therapy. South. Afr. J. HIV Med., 2013, 14(1), 41-43.
[http://dx.doi.org/10.4102/sajhivmed.v14i1.104]
[4]
UNAIDS. UNAIDS sets 90-90-90 target for 2020 to end. AIDS, 2014, 2030 Available from: http://i-base.info/htb/27174
[5]
Lonsbury-Martin, B.L.; Martin, G.K. Evoked Otoacoustic emissions as objective screeners for ototoxicity. Semin. Hear., 2001, 22, 4.
[http://dx.doi.org/10.1055/s-2001-19111]
[6]
Guo, J.J.; Pandey, S.; Doyle, J.; Bian, B.; Lis, Y.; Raisch, D.W. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. Value Health, 2010, 13(5), 657-666.
[http://dx.doi.org/10.1111/j.1524-4733.2010.00725.x] [PMID: 20412543]
[7]
Bankaitis, A.E.; Schountz, T. HIV-related ototoxicity. Semin. Hear., 1998, 19, 155-163.
[http://dx.doi.org/10.1055/s-0028-1082965]
[8]
Khoza-Shangase, K. Is there a need for ototoxicity monitoring in patients with HIV/AIDS? Afr. J. Pharm. Pharmacol., 2010, 4(9), 574-579.
[9]
Tsintis, P.; La Mache, E. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications. Drug Saf., 2004, 27(8), 509-517.
[http://dx.doi.org/10.2165/00002018-200427080-00004] [PMID: 15154824]
[10]
Khoza-Shangase, K. Ototoxicity in tuberculosis treatment in south africa: views from healthcare workers involved in the management of TB. Afr. J. Pharm. Pharmacol., 2013, 7(30), 2141-2145.
[11]
Khoza-Shangase, K.; Stirk, M. Audiological testing for ototoxicity monitoring in adults with Tuberculosis in state hospitals in Gauteng, South Africa. S. Afr. J. Infect. Dis., 2016, 1(1), 1-6.
[12]
Blaschke, T.F.; Nies, A.S.; Mamelok, R.D. Principles of Therapeutics. In: Goodman and Gilman’s The pharmacological basis of therapeutics; 7th ed; Gilman, A.G.; Goodman, L.S.; Rall, T.W., Eds.; Macmillan: New York, 1995; p. 49-65.
[13]
Kallail, K.J.; Downs, D.W.; Schertz, J.W. Communication disorders in individuals with HIV/AIDS. Kansas Journal of Medicine, 200, 62-69. Available from : http://archie.kumc.edu/bitstream/handle/2271/344/Communication+Disorders+in+Individuals+with+HIV-AIDS.pdf?sequence
[14]
Khoza-Shangase, K. Pharmaco-audiology vigilance and highly active antiretroviral therapy (HAART) in South Africa: Ototoxicity Monitoring Pursued. J. AIDS Clin. Res. Sexually Trans. Dis., 2014, 1(1), 1-10.
[http://dx.doi.org/10.24966/ACRS-7370/100001]
[15]
Khoza-Shangase, K. Highly active antiretroviral therapy: Does it sound toxic? J. Pharm. Bioallied Sci., 2011, 3(1), 142-153.
[http://dx.doi.org/10.4103/0975-7406.76494] [PMID: 21430965]
[16]
Bernard, P.A.; Péchère, J.C.; Hébert, R. Altered objective audiometry in aminoglycosides-treated human neonates. Arch. Otorhinolaryngol., 1980, 228(3), 205-210.
[http://dx.doi.org/10.1007/BF00454229] [PMID: 7425950]
[17]
Piek, J.; Lumenta, C.B.; Bock, W.J. Monitoring of auditory function in comatose patients in therapy with potentially ototoxic substances using acoustically evoked brainstem potentials. Anasth. Intensivther. Notfallmed., 1985, 20(1), 1-5.
[18]
Fausti, S.A.; Rappaport, B.Z.; Frey, R.H.; Henry, J.A.; Phillips, D.S.; Mitchell, C.R.; Olson, D.J. Reliability of evoked responses to high-frequency (8-14 kHz) tone bursts. J. Am. Acad. Audiol., 1991, 2(2), 105-114.
[PMID: 1768872]
[19]
Fausti, S.A.; Frey, R.H.; Henry, J.A.; Olson, D.J.; Schaffer, H.I. Early detection of ototoxicity using high-frequency, tone-burst-evoked auditory brainstem responses. J. Am. Acad. Audiol., 1992, 3(6), 397-404.
[PMID: 1486202]
[20]
Campbell, K.C.M. Pharmacology and ototoxicity for Audiologists; Thomson/Delmar Learning: United States, 2007.
[21]
Stavroulaki, P.; Apostolopoulos, N.; Dinopoulou, D.; Vossinakis, I.; Tsakanikos, M.; Douniadakis, D. Otoacoustic emissions--an approach for monitoring aminoglycoside induced ototoxicity in children. Int. J. Pediatr. Otorhinolaryngol., 1999, 50(3), 177-184.
[http://dx.doi.org/10.1016/S0165-5876(99)00247-5] [PMID: 10595663]
[22]
Fausti, S.A.; Henry, J.A.; Helt, W.J.; Phillips, D.S.; Frey, R.H.; Noffsinger, D.; Larson, V.D.; Fowler, C.G. An individualized, sensitive frequency range for early detection of ototoxicity. Ear Hear., 1999, 20(6), 497-505.
[http://dx.doi.org/10.1097/00003446-199912000-00005] [PMID: 10613387]
[23]
Vaughan, N.E.; Fausti, S.A.; Chelius, S.; Phillips, D.; Helt, W.; Henry, J.A. An efficient test protocol for identification of a limited, sensitive frequency test range for early detection of ototoxicity. J. Rehabil. Res. Dev., 2002, 39(5), 567-574.
[PMID: 17642021]
[24]
Bess, F.H.; Humes, L.E. Audiology: The fundamentals; Williams & Wilkins: Baltimore, 1990.
[25]
Hall, J.W. Handbook of otoacoustic emissions; , 2000.
[26]
Friedmann, I.; Arnold, W. Pathology of the ear. J. Pathol., 1994, 174, 63.
[27]
Katz, J. Handbook of clinical audiology; Williams & Wilkins: Baltimore, 2002.
[28]
Meyerhoff, W.L.; Maale, G.E.; Yellin, W.; Roland, P.S. Audiologic threshold monitoring of patients receiving ototoxic drugs. Preliminary report. Ann. Otol. Rhinol. Laryngol., 1989, 98(12 Pt 1), 950-954.
[http://dx.doi.org/10.1177/000348948909801206] [PMID: 2589763]
[29]
Skinner, R.; Pearson, A.D.J.; Amineddine, H.A.; Mathias, D.B.; Craft, A.W. Ototoxicity of cisplatinum in children and adolescents. Br. J. Cancer, 1990, 61(6), 927-931.
[http://dx.doi.org/10.1038/bjc.1990.208] [PMID: 2372498]
[30]
Dreschler, W.A.; van der Hulst, R.J.A.M.; Tange, R.A.; Urbanus, N.A. Clinical Aspects. Role of high-frequency audiometry in the early detection of ototoxicity. II. Audiology, 1989, 28(4), 211-220.
[http://dx.doi.org/10.3109/00206098909081626] [PMID: 2751489]
[31]
Dreisbach, L.E.; Long, K.M.; Lees, S.E. Repeatability of high-frequency distortion-product otoacoustic emissions in normal-hearing adults. Ear Hear., 2006, 27(5), 466-479.
[http://dx.doi.org/10.1097/01.aud.0000233892.37803.1a] [PMID: 16957498]
[32]
Frank, T. High-frequency hearing thresholds in young adults using a commercially available audiometer. Ear Hear., 1990, 11(6), 450-454.
[http://dx.doi.org/10.1097/00003446-199012000-00007] [PMID: 2073979]
[33]
American Speech-Language-Hearing Association. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA, 1994, 36(12), 11-19.
[34]
Feghali, J.G.; Bernstein, R.S. A new approach to serial monitoring of ultra-high frequency hearing. Laryngoscope, 1991, 101(8), 825-829.
[http://dx.doi.org/10.1288/00005537-199108000-00005] [PMID: 1865730]
[35]
Hall, A.J.; Lutman, M.E. Methods for early identification of noise-induced hearing loss. Audiology, 1999, 38(5), 277-280.
[http://dx.doi.org/10.3109/00206099909073035] [PMID: 10548376]
[36]
Mulheran, M.; Degg, C. Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects. Br. J. Audiol., 1997, 31(1), 5-9.
[http://dx.doi.org/10.3109/03005364000000004] [PMID: 9056039]
[37]
Ress, B.D.; Sridhar, K.S.; Balkany, T.J.; Waxman, G.M.; Stagner, B.B.; Lonsbury-Martin, B.L. Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Third place--Resident Clinical Science Award 1998. Otolaryngol. Head Neck Surg., 1999, 121(6), 693-701.
[http://dx.doi.org/10.1053/hn.1999.v121.a101567] [PMID: 10580222]
[38]
Arnold, D.J.; Lonsbury-Martin, B.L.; Martin, G.K. High-frequency hearing influences lower-frequency distortion-product otoacoustic emissions. Arch. Otolaryngol. Head Neck Surg., 1999, 125(2), 215-222.
[http://dx.doi.org/10.1001/archotol.125.2.215] [PMID: 10037289]
[39]
Avan, P.; Elbez, M.; Bonfils, P. Click-evoked otoacoustic emissions and the influence of high-frequency hearing losses in humans. J. Acoust. Soc. Am., 1997, 101(5 Pt 1), 2771-2777.
[http://dx.doi.org/10.1121/1.418564] [PMID: 9165731]
[40]
Biró, K.; Baki, M.; Büki, B.; Noszek, L.; Jókúti, L. Detection of early ototoxic effect in testicular-cancer patients treated with cisplatin by transiently evoked otoacoustic emission: a pilot study. Oncology, 1997, 54(5), 387-390.
[http://dx.doi.org/10.1159/000227724] [PMID: 9260600]
[41]
Franklin, D.J.; McCoy, M.J.; Martin, G.K.; Lonsbury-Martin, B.L. Test/retest reliability of distortion-product and transiently evoked otoacoustic emissions. Ear Hear., 1992, 13(6), 417-429.
[http://dx.doi.org/10.1097/00003446-199212000-00008] [PMID: 1487104]
[42]
Zhao, F.; Stephens, D. Test-retest variability of distortion-product otoacoustic emissions in human ears with normal hearing. Scand. Audiol., 1999, 28(3), 171-178.
[http://dx.doi.org/10.1080/010503999424743] [PMID: 10489866]
[43]
Beattie, R.C.; Ireland, A. Effects of sample size on the noise floor and distortion product otoacoustic emissions. Scand. Audiol., 2000, 29(2), 93-102.
[http://dx.doi.org/10.1080/010503900424507] [PMID: 10888346]
[44]
Beattie, R.C.; Kenworthy, O.T.; Luna, C.A. Immediate and short-term reliability of distortion-product otoacoustic emissions. Int. J. Audiol., 2003, 42(6), 348-354.
[http://dx.doi.org/10.3109/14992020309101328] [PMID: 14570243]
[45]
Campbell, K.C.M.; Durrant, J. Audiologic monitoring for ototoxicity. Otolaryngol. Clin. North Am., 1993, 26(5), 903-914.
[PMID: 8233496]
[46]
Arlinger, S. Technical aspects on stimulation, recording and signal processing. Scand. Audiol. Suppl., 1981, 13, 41-53.
[PMID: 6944777]
[47]
Baer, J.E.; Hall, J.W. Effects of nonpathologic factors on otoacoustic emissions. Hear. J., 1992, 45, 17-23.
[48]
Jacobson, J.T.; Hyde, M.L. An introduction to auditory evoked potentials.Handbook of clinical audiology, 3rd ed; Katz, J., Ed.; Williams & Wilkins: Baltimore, 1985, pp. 496-533.
[49]
Popelka, G.R.; Karzon, R.K.; Clary, R.A. Identification of noise sources that influence distortion product otoacoustic emission measurements in human neonates. Ear Hear., 1998, 19(4), 319-328.
[http://dx.doi.org/10.1097/00003446-199808000-00007] [PMID: 9728727]
[50]
GSI 60 DPOAE user manual. Milford NH: GSI Grason-Stadler, 1996.
[51]
Martin, F.N.; Clark, J.G. Introduction to audiology, 8th ed; Allyn & Bacon: Boston, 2003.
[52]
American Academy of Audiology. Position statement and clinical practice guidelines: Ototoxicity monitoring. 2009. Available from : www.audiology.org/resources/documentlibrary/Documents/OtoMonPositionGuideline.pdf
[53]
Ludman, L.; Wright, T. Diseases of the ear; Arnold Publishers: London, 1998.
[54]
Le Prell, C.G.; Ojano-Dirain, C.; Rudnick, E.W.; Nelson, M.A.; DeRemer, S.J.; Prieskorn, D.M.; Miller, J.M. Assessment of nutrient supplement to reduce gentamicin-induced ototoxicity. J. Assoc. Res. Otolaryngol., 2014, 15(3), 375-393.
[http://dx.doi.org/10.1007/s10162-014-0448-x] [PMID: 24590390]
[55]
Wissink, T.F.; Moes, C.; Beisel, K.W. Neurotrophins and Hearing Dysfunction: Comparing models to stop nerve fiber loss. Drug Discov. Today, 2006, 3(4), 391-396.

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy